GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...
Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...
Hosted on MSN2mon
GSK gets expanded EU approval for Jemperli in endometrial cancerFDA approval for Jemperli plus chemotherapy was expanded to include all adult patients with primary advanced or recurrent endometrial cancer in August 2024. More on GSK GSK plc (GSK) 43rd Annual J ...
In the US in 2024, there were over 152,000 new cases of colorectal cancer ... endometrial cancer, both as a standalone therapy (monotherapy) or in combination with chemotherapy. Jemperli ...
Dostarlimab was approved as Jemperli for the treatment of endometrial cancer, and is a potential blockbuster drug, which made some ~$600mn in annual sales last year. However, things have soured ...
Regulatory bodies, including the FDA, are accelerating approvals for new therapies, such as the 2024 approval of Jemperli in combination with chemotherapy, marking a significant milestone in treating ...
Regulatory bodies, including the FDA, are accelerating approvals for new therapies, such as the 2024 approval of Jemperli in combination with chemotherapy, marking a significant milestone in treating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback